Actively Recruiting
Hypofractionation (Radiation) Trial for Multiple Myeloma
Led by University of Chicago · Updated on 2026-03-30
30
Participants Needed
1
Research Sites
138 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study if for people who have been diagnosed with multiple myeloma and their doctors are recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of external beam radiation therapy. Doctors leading this study would like to see if a shorter radiation course (i.e., hypofractionation) for pelvic radiation is safe for multiple myeloma. Because participants in this study will receive a shortened radiation course, each daily treatment dose that is delivered would be slightly higher than normal. This higher daily dose would be delivered because the study team would like to see if higher doses of radiation are as safe given over a shorter number of days compared to 2-3 weeks. The purpose of this study is to make sure that hypofractionation is safe and effective for individuals with multiple myeloma.
CONDITIONS
Official Title
Hypofractionation (Radiation) Trial for Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent before any study procedures
- Men or women aged 18 years or older
- Clinically confirmed relapsed or refractory multiple myeloma with up to 5 bone lesions suitable for radiation
- Measurable disease with tumor lesions between 0.25 cc to 65 cc in size
- Eastern Cooperative Oncology Group performance status of 2 or better
- Adequate organ function confirmed by lab tests
- Women of childbearing potential must have a negative pregnancy test within 72 hours before starting and agree to use contraception during and up to 5 months after treatment
- Men sexually active with women of childbearing potential must agree to contraception during and up to 7 months after treatment and avoid sperm donation
- Women who are breastfeeding or pregnant are excluded
You will not qualify if you...
- Spinal instability neoplastic score (SINS) greater than 13 or Mirels' score greater than 9
- Receiving concurrent anti-myeloma or systemic therapy
- Not recovered from adverse events related to prior treatments (except steroids, neuropathy grade 2 or less, or alopecia)
- Prior radiation therapy delivering more than 10% dose to the planned treatment area
- Chemotherapy within 2 weeks or monoclonal antibody/small molecule therapy within 7 days before radiation
- Known additional malignancies that could interfere with study results unless approved by investigator
- History of non-infectious pneumonitis requiring steroids or evidence of interstitial lung disease
- Current seizure disorder
- Any condition or abnormality interfering with participation or study results as judged by investigator
- Psychiatric or substance abuse disorders interfering with cooperation
- Pregnant, breastfeeding, or planning to conceive or father children during the study and 120 days after last dose
- Active Hepatitis B or C infection if treating liver lesions
- Significant cardiovascular disease including recent heart attack, stroke, uncontrolled angina, serious arrhythmias, severe heart failure, or oxygen dependency
- Concurrent use of statins unless stable for over 3 months without CK rise
- Clinically significant muscle disorders or conditions elevating creatine kinase levels
- Prisoners or involuntarily incarcerated individuals
- Compulsory detention for psychiatric or physical illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
Y
Yasmin Hasan, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here